Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.

Cancer Med · 2019 · PMC6792497 · PMID 31444999

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Interestingly, Carbonic anhydrase IX (CAIX) (a biomarker of hypoxia) shows a nonsignificant trend for increase at day 2, but no change at the end of treatment.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.